证券代码：300573 证券简称：兴齐眼药 公告编号：2025-065 沈阳兴齐眼药股份有限公司 2025 年第三次临时股东会决议公告 1、会议召开方式：本次会议以现场投票与网络投票相结合的方式召开。 2、现场会议时间：2025年12月17日（星期三）下午14:30。 3、网络投票时间：2025年12月17日，其中，通过深圳证券交易所交易系统 进行网络投票的具体时间为2025年12月17日9:15—9:25，9:30—11:30和13:00 —15:00；通过深圳证券交易所互联网投票系统进行网络投票的时间为2025年12 月17日9:15至15:00期间的任意时间。 4、现场会议召开地点：沈阳市沈河区青年大街125号企业广场B座30层。 5、会议召集人：公司董事会。 6、会议主持人：公司董事长刘继东先生。 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决议案的情形； 2、本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 1、审议通过《关于变更公司住所并修订公司章程的议案》 同意 81,709,055 股， ...

（文章来源：证券日报） 证券日报网讯 12月15日晚间，兴齐眼药发布公告称，公司原有的《药品生产许可证》将于2025年12月 22日到期。近日公司收到辽宁省药品监督管理局换发的《药品生产许可证》，同时核减生产范围"溶液 剂（眼用）、吸入制剂（101车间生产二区2线）、大容量注射剂"。 ...

Core Viewpoint - The company, Xingqi Eye Medicine (300573.SZ), has received a new "Drug Production License" from the Liaoning Provincial Drug Administration, which will replace its existing license expiring on December 22, 2025. The new license has reduced the scope of production for certain categories of products [1]. Group 1 - The existing "Drug Production License" is set to expire on December 22, 2025 [1] - The company has received a new "Drug Production License" from the Liaoning Provincial Drug Administration [1] - The production scope has been reduced to exclude "solution dosage forms (ophthalmic), inhalation preparations (workshop 101 production area line 2), and large-volume injections" [1]

Core Viewpoint - The company, Xingqi Eye Medicine, has received a new Drug Production License from the Liaoning Provincial Drug Administration, which will replace its existing license expiring on December 22, 2025. The new license has reduced the scope of production for certain products [1]. Group 1 - The existing Drug Production License of the company will expire on December 22, 2025 [1] - The company has received a new Drug Production License from the Liaoning Provincial Drug Administration [1] - The new license has reduced the production scope to exclude "solution dosage forms (ophthalmic), inhalation preparations (workshop 101 production area 2 line), and large-volume injections" [1]

证券代码：300573 证券简称：兴齐眼药 公告编号：2025-064 沈阳兴齐眼药股份有限公司 关于取得换发《药品生产许可证》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 沈阳兴齐眼药股份有限公司（以下简称"公司"）原有的《药品生产许可证》 将于2025年12月22日到期。近日公司收到辽宁省药品监督管理局换发的《药品生 产许可证》，同时核减生产范围"溶液剂（眼用）、吸入制剂（101车间生产二区2 线）、大容量注射剂"，新药品生产许可证主要信息如下： 企业名称：沈阳兴齐眼药股份有限公司 许可证编号：辽 20150024 社会信用代码：912101001179988209 有效期至：2030 年 12 月 10 日 生产地址和生产范围：沈阳市浑南区泗水街 68 号：滴眼剂，眼用凝胶剂， 眼膏剂，吸入制剂，耳用制剂[滴耳剂（无菌）]，涂剂*** 以上变更不会对公司生产经营产生重大影响，敬请广大投资者理性投资，注 意投资风险。 分类码：AhBhCh 住所（经营场所）：中国（辽宁）自由贸易试验区沈阳片区新运河路 25 号 法定代表人：刘继东 企业负责人：高峨 ...

Group 1 - Jinggong Technology signed a sales contract with Hubei Yuchuang worth 729 million yuan, accounting for 42.16% of the company's audited revenue for 2024 [1] - Heshun Electric is expected to win a bid for a State Grid procurement project worth 107 million yuan, representing 24.97% of the company's 2024 revenue [2] - Yongmaotai plans to invest approximately 400 million yuan in a new intelligent manufacturing project for magnesium-aluminum alloy materials [3] Group 2 - Longi Green Energy announced the termination of its plan to issue global depositary receipts abroad, stating it will not significantly impact its operations [4] - Bai Ao Intelligent is expected to win bids for projects totaling 27.5 million yuan [5] - Lian Biological is planning a change of control and asset purchase, leading to a temporary suspension of its stock [6] Group 3 - Bo Rui Communication intends to acquire 51% of Meijing Technology for 66.49 million yuan [7] - Huitai Medical plans to repurchase shares worth 200 to 250 million yuan for employee stock ownership plans [8] - Yifang Biological is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange [9] Group 4 - Jiuqiang Biological's shareholders signed an agreement for the transfer of 5% of the company's shares to China National Pharmaceutical Investment [11] - Songcheng Performing Arts plans to repurchase shares worth 100 to 200 million yuan for capital reduction [12] - Zhonghong Medical's subsidiary is expected to be selected for a centralized procurement project in Jiangxi Province [13] Group 5 - Xingfu Electronics plans to invest 480 million yuan in a new electronic-grade phosphoric acid project [14] - Jiaao Environmental Protection's stock will be subject to risk warnings due to an administrative penalty [15] - ST Nuotai received a drug registration certificate for a new injection [16] Group 6 - Haimo Technology plans to sell its controlling subsidiary, Xian Sitian Instrument, for 370 million yuan [17] - Jingce Electronics signed multiple sales contracts with a single customer totaling 433 million yuan [18] - Donghua Testing's controlling shareholder plans to reduce its stake by up to 1.99% [19][20] Group 7 - Xingqi Eye Medicine completed the first subject enrollment for a Phase II clinical trial of its eye drop product [21] - Kute Intelligent's controlling shareholder plans to reduce its stake by up to 2% [22] - Dongcheng Pharmaceutical's subsidiary received approval for a new specification of a heparin sodium injection [23] Group 8 - Zhaoyi Innovation is in the process of issuing H-shares and has received regulatory approval [24] - Aokang International's shareholder plans to reduce its stake by up to 3% [25] - Jiamei Packaging's controlling shareholder is planning a change of control, leading to a temporary stock suspension [26] Group 9 - ST Kevin's stock will have its risk warning lifted and will resume trading [27] - Zaiseng Technology's controlling shareholder plans to transfer 6.04% of the company's shares [28] - Lide New Energy's shareholder plans to reduce its stake by up to 1% [29] Group 10 - Srypu terminated its plan to acquire shares and will resume trading [30] - Longjiang Transportation's subsidiary plans to invest 2.679 billion yuan in a graphite mining project [31] - Haowei Group's controlling shareholder has not reduced its stake and has terminated the reduction plan [32] Group 11 - Huilun Crystal received an administrative penalty notice for information disclosure violations [33] - Haiguang Information terminated a major asset restructuring plan [34] - Zhongke Shuguang announced a cash dividend plan [35] Group 12 - Fushuo Technology's share purchase plan was approved by the Shenzhen Stock Exchange [36] - Dongbai Group's shareholder reduced its stake by 25.95 million shares [38]

Core Viewpoint - The company has initiated the Phase II clinical trial for its SQ-22031 eye drops, aimed at treating moderate to severe dry eye syndrome, marking a significant step in its research and development efforts [1] Group 1: Clinical Trial Details - The SQ-22031 eye drops have completed the enrollment of the first subject in a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study [1] - The primary objective of the Phase II study is to evaluate the efficacy and safety of SQ-22031 eye drops in patients with moderate to severe dry eye [1] - The study will also analyze the immunogenicity of the product and its impact on corneal nerve density changes [1]

Core Viewpoint - The company Xingqi Eye Medicine (300573) has announced the initiation of a Phase II clinical trial for its eye drop product SQ-22031, aimed at treating moderate to severe dry eye syndrome, with the first subject enrolled in the study [1] Group 1 - The clinical trial for SQ-22031 is a multicenter, randomized, double-blind, placebo-controlled study [1] - As of now, there are no approved drugs of the same category listed on the National Medical Products Administration's website [1]

证券代码：300573 证券简称：兴齐眼药 公告编号：2025-063 沈阳兴齐眼药股份有限公司 剂型：滴眼液 适应症：干眼 临床试验批准通知书编号：2024LP01683、2024LP01684、2024LP01685、 2024LP01686 关于SQ-22031滴眼液治疗中至重度干眼Ⅱ期临床试验 首例受试者入组的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 沈阳兴齐眼药股份有限公司（以下简称"公司"）研发的SQ-22031滴眼液 于今日完成了"一项评估SQ-22031滴眼液治疗中至重度干眼的有效性和安全性 的多中心、随机、双盲、安慰剂对照的Ⅱ期临床研究"首例受试者入组，正式 进入Ⅱ期临床试验。现将有关内容公告如下： 一、基本情况 药物名称：SQ-22031滴眼液 注册分类：治疗用生物制品1类 临床试验分期：Ⅱ期 二、临床试验相关情况 干眼（Dry Eye，DE）是一类多因素导致的眼表疾病，表现为泪液的质、量 及流体动力学异常引起的泪膜不稳定或眼表微环境失衡，可伴有泪液渗透压升高 以及眼表组织炎性反应、损伤、神经异常，临床出现眼部干涩、烧灼感、畏光 ...

融券方面，当日融券卖出1.26万股，融券偿还4500.0股，融券净卖出8100.0股，融券余量12.66万股，近3 个交易日已连续净卖出累计1.2万股，近20个交易日中有11个交易日出现融券净卖出。 | 交易日 | 融) 田學院論 | | 融券会量(股) | 融券余额(元) | | --- | --- | --- | --- | --- | | 2025-12-08 | | 8100.0 | 12.66万 | 925.23万 | | 2025-12-05 | | 3600.0 | 11.85万 | 864.61万 | | 2025-12-04 | | 300.0 | 11.49万 | 843.97万 | | 2025-12-03 | | -1800.0 | 11.46万 | 817.13万 | | 2025-12-02 | | 2000.0 | 11.64万 | 831.24万 | 融资融券余额11.77亿元，较昨日上涨0.26%。 证券之星消息，12月8日，兴齐眼药（300573）融资买入5013.21万元，融资偿还4765.73万元，融资净买 入247.49万元，融资余额11.68亿元，近3个交易日已连续 ...